Thanich SangsuwannukulKamonlapat SupimonJatuporn SujjitjoonNattaporn PhanthapholThaweesak ChieochansinNaravat PoungvarinSopit WongkhamMutita JunkingPa thai YenchitsomanusKhon Kaen UniversityFaculty of Medicine, Siriraj Hospital, Mahidol University2020-12-282020-12-282020-12-01International Immunopharmacology. Vol.89, (2020)18781705156757692-s2.0-85097147853https://repository.li.mahidol.ac.th/handle/20.500.14594/60488© 2020 Elsevier B.V. Current treatment of cholangiocarcinoma (CCA) – a lethal bile duct cancer – is ineffective because the disease is usually diagnosed at late and advanced stage. Thus, a novel therapeutic modality is urgently required. Fourth-generation chimeric antigen receptor (CAR4) T cells was created to target CD133, a well-known cancer stem cell marker, that is highly expressed and associates with cancer progression. The anti-CD133-CAR4 T cells showed high efficacy against CD133-expressing CCA cells. Tumour cell lysis occurred in a dose- and CD133 antigen-dependent manner, and significantly higher, up to 57.59% ± 9.62 at effector to target ratio of 5:1 in a CCA cell line – KKU-213A cells, compared to mock control (p = 0.008). Similarly, significant IFN-γ (p = 0.011) and TNF-α (p = 0.002) upregulation was observed upon tumour treatment. The effectiveness of our anti-CD133-CAR4 T cells will be beneficial not only for CD133-expressing CCA, but also for other CD133-expressing tumours. This study may guide future in vivo study and clinical trials.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1016/j.intimp.2020.107069